key: cord-1039603-13e4wiwd authors: Luong, Albert D.; Buzid, Alyah; Vashist, Sandeep K.; Luong, John H.T. title: Perspectives on electrochemical biosensing of COVID-19 date: 2021-07-03 journal: Curr Opin Electrochem DOI: 10.1016/j.coelec.2021.100794 sha: d8ba4e4e2ed1a49ca61a15ac6378cfc3c58f6450 doc_id: 1039603 cord_uid: 13e4wiwd Rapid detection of human coronavirus 2019, termed as SARS-CoV-2 or COVID-19 infection is urgently needed for containment strategy due to its unprecedented spreading. Novel biosensors can be deployed in remote clinical settings without central facilities for infection screening. Electrochemical biosensors serve as analytical tools for rapid detection of viral structure proteins, mainly spike (S) and nucleocapsid (N) proteins, human immune responses, reactive oxygen species (ROS), viral ribonucleic acid, polymerase chain reaction byproducts, and other potential biomarkers. The development of point of care testing (POCT) devices is challenging due to the requirement of extensive validation, a time-consuming and expensive step. Together with specific biorecognition molecules, nanomaterials enabled-based biosensors have emerged for the fast detection of early viral infections. A single and positive-stranded RNA virus [1] (SARS-CoV-2) has infected people and caused deaths worldwide [2] . To date, more than 173 M people have been infected, resulting in >3.7 M death (https://www.worldometers.info/coronavirus/coronavirus-cases/accessed 6.6.21). Affected subjects have experienced severe, mild, or no symptoms [3, 4] , thus, fast analysis of viral infection is of uttermost importance to isolate affected people. Although opacities in computed tomography images were observed in affected patients with pneumonia [5] [6] [7] , this diagnosis is not always reliable. The viral genetic code deciphered in early January 2020 enables the development of polymerase chain reaction (PCR) for detecting its distinct ribonucleic acid (RNA) sequences [8] . The viral RNA consists of double-layered lipid enveloped with four major structural proteins (Figure 1 ). Four known structural proteins of SARS-CoV-2 (created by BioRender.com). The abundant S protein (∼150 kDa with 1255 amino acids, AA) mediates viral attachment to the host cell surface receptors (ACE2), followed by viral infusion and entry. The motif KRSFIEDLLFNKV occurs in the spike glycoprotein that binds ACE2. The M protein (∼25-30 kD with 221 AA) is the most abundant: defines the viral envelope shape and participates in viral production and maturation. The smallest E protein (∼8-12 kDa, 76 AA) is involved in viral budding and assembly, directing protein-protein interceptions and inducing membrane curvature, and preventing M protein aggregation. Based on its binding to the RNA genome, the N protein participates in viral assembly and budding [2] . The N protein is the most immunogenic viral structural protein that is shed just a few days after infection with a peak at around 10 days postinfection. Real-time reverse-transcription PCR (RT-PCR) has been developed to target various viral genes [9] (Table 1) . Acute infection with SARS-CoV-2 also invokes the release of antibodies against specific viral antigens in serum within days to weeks [10] . [ [10] [11] [12] [13] [14] Immunoassays -Infection with SARS-CoV-2 initiates the release of antibodies against specific viral N and S antigens: specific anti-S protein antibodies against the spike's S1 protein subunit and receptor-binding domains (RBD). -These antibodies are released in serum within days to weeks following acute infection. Thus, serologic testing cannot be used to diagnose acute SARS-CoV-2 infection. -However, serologic tests can identify persons with resolving or past SARS-CoV-2 infection. [10] Biosensing/diagnostic assays -The detection of two viral proteins (S and N) opens the possibility for probing parts of the intact virus without any sample step. This opinion provides an overview of emerging electrochemical detection tools for effective coronavirus diagnostic assays, encompassing the identification of viral nucleic acids, viral proteins (antigens), PCR byproducts, and reactive oxygen species (ROS). The detection of RNA by RT-PRC is time-consuming and does not have the screening capacity. Point-of-care testing (POCT) alleviates the burden of the testing load on central hospitals without compromising accuracy and detection selectivity for early detection and treatment of viral infection. Loop-mediated isothermal amplification (LAMP) [15] and recombinase polymerase amplification (RPA) can detect the lowest copy number of nucleic acids. Real-time PCR for POCT has been commercialized [16] to process a single sample or multiple samples, up to 80 samples [17] . The topic of POC-PCR assays for COVID-19 detection was recently reviewed by Gupta et al. [18] . Serological tests based on antibodies, antigens, and some biomarkers of infected people are more rapid and inexpensive [19] . Due to the lack of detection sensitivity with a high falsepositive/negative rate, such tests cannot confirm viral infection [20] . The electroanalysis of DNA hybridization is well investigated using a specific DNA sequence, known as a DNA probe. This short single-stranded DNA (ssDNA) is thiolated and selfassembled on a gold surface or a gold nanoparticle (AuNPs) modified electrode. A binding event occurs when the double-stranded DNA (dsDNA) is hybridized with its complementary DNA strand [23] . The binding event can be probed directly or by indirect measurement in the presence of an electroactive marker such as a metal complex or methylene blue [24, 25] . A miniaturized, label-free electrochemical platform can be interfaced with a workstation or smartphone system as shown in Figure 2 [26]. One of its major drawbacks for potential POCT is the requirement of a rapid on-site extraction method for DNA. Nonspecific protein binding on gold is problematic despite unreacted gold being thoroughly blocked by small organic molecules with thiol groups. and SARS-CoV-1 is ~76% and 90%, respectively [27] , and two proteins are highly immunogenic and abundantly during infections. Commercial antibodies against viral proteins; spike (S1 and S2), nucleocapsid (N), envelope (E), ORF, and NSP are available in several countries, particularly, China. As expected, they are expensive, ranging from 5,000 to 6,000 $ US/mg of protein [28] . Some methods are available to prepare antibodies or antibody-like proteins against the spike protein S1 subunit [29] . The S protein assists in binding the virus to the cellular human receptor; thus, it is responsible for inducing the infection [30] . Graphene with a high surface area offers fast electron transfer kinetics and excellent detection sensitivity. A biosensor based on a graphene-field effect transistor (GFET) can detect the virus in clinical samples [31] . The S protein antibody is covalently conjugated to a graphene sheet ( Figure 3A) . A multiplexed telemedicine platformbased laser engraved graphene (LEG) electrode detects several specific biomarkers in saliva and blood [32] . A cell-based biosensor can detect the viral S protein using an array of eight Au screen-printed electrodes [33] . The potentiometric signal is generated upon the addition of the S protein into the membrane-engineered mammalian kidney cells down to 1 fg/mL within 3 min The specific binding between the S protein and GFET results in dose-dependently changing the surface potential [31] . The GFET biosensor can detect SARS-CoV-2 in phosphate-buffered saline, universal transport medium (UTM), the culture medium, and in-patient samples at 1 fg/mol, 100 fg/mol, 16 pfu/mL, and 242 copies/mL, respectively [31] . (B) A wireless graphenebased telemedicine platform equipped with a mobile user interface. This platform detects several specific biomarkers including N-protein, IgG, and IgM antibodies, and inflammatory biomarker C-reactive protein. Different recognition receptors are covalently conjugated to graphene, followed by blocking unreacted sites by bovine serum albumin. Reproduced with permission from Ref. [32] . (C) A schematic diagram of a Co-functionalized TiO 2 nanotube (Co-TNT)-based sensing platform [36] . Reproduced with permission from Ref. [36] . Reactive PCR products. GenMark Diagnostics launched a rapid test, known as ePlex® to detect amplified products of PCR. Qualitative viral detection in nasopharyngeal swab specimens is based on a single-use cartridge and proprietary surface electrowetting. The USFDA has approved this test for Emergency Use Authorization (EUA) [37] . Based on the hybridization of competitive DNA, electrochemical detection by a capture probe immobilized on a gold-plated J o u r n a l P r e -p r o o f electrode. The viral RNA extracted from the specimen by magnetic solid-phase extraction is converted to cDNA followed by PCR amplification. A ferrocene-labeled signal probe is then mixed with the target DNA. Upon the hybridization of the target DNA, the ferrocene-labeled signal probe generates an electrochemical response. The test has a LOD of 1 x 10 5 copies/mL for the SARS-CoV-2 DNA [38] , which is comparable to the approved RT-PCR for EUA [39] . Upon the inflammation of the lungs with SARS-CoV, the respiratory system underlays molecular mechanisms: pyrin domain-containing 3 (NLRP3), a nod-like receptor family, is activated by the virus [40] and then releases ROS to damage mitochondria [41, 42] . Sputum is one of the most secreted samples with a high viral load in the lung epithelium [43] . A real-time sensor based on the fabrication of multiwalled carbon nanotubes (CNTs) on the steel needle tip was designed to detect ROS in patients' samples [44] ( Figure 4 ). Asymptomatic cases of SARS-CoV-2 have made the diagnosis more complex by physical examination or chest X-rays. Portable PCR and immunoassays are commercially available for different viral genes, human immune proteins, and pertinent biomarkers to alleviate the burden of testing. AuNPs together with a recombinant viral antigen and rabbit-IgG can be used in lateral flow immunoassays of IgM and IgG in human blood within 15 min [45] . Nevertheless, simple electrochemical approaches are powerful tools for POCT, doctors' offices in remote areas, or countries with limited resources. S protein and N protein are considered the prime targets due to their abundance and high immunogenicity, and the biorecognition molecules are based on exorbitantly expensive poly/monoclonal antibodies for these two proteins. The envelope (E) and membrane (M) proteins are required for virus assembly [46] , however, they are nonspecific biomarkers for SARS-CoV-2. The biorecognition molecules are polyclonal or monoclonal antibodies, which are commercially available from different sources. The ACE2 has rarely been used, due to its commercial high cost, and must be kept at -20 to -70 C to conserve its stability [47]. Single-stranded RNA or DNA oligonucleotides can also serve as specific recognition biomolecules. A search of small molecules with selective binding to S and N proteins is critical for developing POCT. For POCT, a "true" one-step is desirable as the user simply swirls the sample to the detection device. To date, applications of nanomaterials are limited [48] , and electrochemical approaches have competed with colorimetry and surface plasmon resonance (SPR). Both S and N proteins must be analyzed simultaneously to circumvent potential crossreaction with other endemic coronaviruses or viral mutations. Other biomarkers such as Creactive protein, interleukin-6 (IL-6), D-dimer, etc. also assist the prognosis of SARS-CoV-2. The commonest sample is a swab from the patient's nose or throat with an expected notable viral Due to the anticipated non-electroactivity of antibodies, viral antigens, and nucleic acids, impedance spectroscopy is a detection method of choice over other electrochemical methods. Biosensors for POCT are also needed to detect viral infection in urine, blood, saliva, and stools. POCT tests must be validated in appropriate populations and settings, a time-consuming and expensive step. Electroanalysis can be combined with complementary methods, mainly microquartz balance and SPR toward the development of more reliable biosensors [50] . Of importance for POCT are the paper-based sensors for nucleic acids [51] , and SARS-CoV-2 antibodies [52] . Another important parameter is the dissociation constant (k D ), which can be used to differentiate the binding of SARS-CoV-2 S to human ACE2 (k D =14.7 nM)) over SARS-CoV S (k D = 325.8 nM) [53] . Transplant patients generate T cell response but not anti-SARS-CoV-2 antibodies after infection [54] . Therefore, it is of uttermost importance to engineering a multiplex biosensor that can detect both T cells and antibodies [55] . Of further interest is the development of various CRISPR (clustered short palindrome repeats with regular intervals)-Cas (CRISPR associated proteins) detection platforms for detecting COVID-19 [56] [57] [58] [59] . Immunoassays have been miniaturized and adapted for POCT to target antibodies in blood, serum, and plasma [45, 60, 61] or viral antigens in nasopharyngeal [21, [62] [63] [64] [65] [66] [67] . Rapid PCR methods [68] [69] [70] [71] [72] and isothermal amplification [73, 74] for POCT are also commercially available. Apart from clinical diagnostics, the demand for surveillance systems and devices that can detect this virus in the air (aerosols) and water is likely to increase. The vast literature information of electrode materials, nanomaterials, and sensing methods is available for viral detection. [77]. Therefore, continuous improvement in diagnostic assays is critical to ensure reliable detection of SARS-CoV-2 infection from different variants [78] . The coronavirus infection produces a large repertoire of cytokines [79] , which could be exploited toward the development of POC devices. POCT eliminates the storage and delivery of collected samples to central labs as collected samples must be stored at 2-8°C to preserve sample stability. POC sensing also reduces the risk of sample cross-contamination. As sample transportation might take a few hours or longer, POCT ultimately reduces the turn-around time appreciably, i.e., the time duration between sample registrations to reporting of results. The authors declare that they have no known competing financial interests. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update *The authors discuss small molecules that bind the COVID-19 spike protein as potential drugs to inhibit the viral entry into host cells Presumed asymptomatic carrier transmission of COVID-19 Transmission of 2019-nCoV infection from an asymptomatic contact in Germany Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan COVID-19): role of chest CT in diagnosis and management *The paper unravels single-step quantitative real-time reverse-transcription PCR to detect ORF1b and N of the viral genome in human samples Laboratory testing for coronavirus disease (COVID-19) in suspected human cases Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis Comparison of seven commercial RT-PCR diagnostic kits for COVID-19 Limits of detection of 6 approved RT-PCR kits for the novel SARS-coronavirus-2 (SARS-CoV-2) Mini review: recent progress in RT-LAMP enabled COVID-19 detection Point-of-care testing detection methods for COVID-19 Point-of-care PCR assays for COVID-19 detection Diagnostic performance of commercially available COVID-19 serology tests in Brazil Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies Abbott realtime SARS-CoV-2 assay *This commercial assay provides a fully automated solution to help laboratories to provide qualitative detection of nucleic acids from SARS-CoV-2 in response to the urgent need for automated Antibody responses to SARS-CoV-2 in patients with COVID-19 *The authors report acute antibody responses to SARS-CoV-2 in patients with COVID-19. Serological testing for IgG and IgM is helpful for the diagnosis of suspected patients with negative RT-PCR results and/or asymptomatic infections Chemical sensors and biosensors: fundamentals and applications *Sodium aurothiomalate as an electroactive label in a DNA hybridization biosensor for the electrochemical detection of a SARS virus sequence Trends in DNA biosensors Label-free electrochemical detection of DNA hybridization: A method for COVID-19 diagnosis Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV SARS-CoV-2 antibodies Antibody-like proteins that capture and neutralize SARS-CoV-2 6:eabd3916. *The authors reported an in vitro selection of multiple high affinity antibody-like proteins against various targets including the SARS-CoV-2 spike protein Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor *The authors report a field-effect transistor (FET)-based biosensing device by coating graphene sheets of the FET with a specific antibody against SARS-CoV-2 spike protein to detect the SARS-CoV-2 spike protein SARS-CoV-2 rapidplex: A graphene-based multiplexed telemedicine platform for rapid and low-cost COVID-19 diagnosis and monitoring Development of a portable, ultrarapid and ultra-sensitive cell-based biosensor for the direct detection of the SARS-CoV-2 S1 spike protein antigen eCovSens-ultrasensitive novel in-house built printed circuit board based electrochemical device for rapid detection of nCovid-19 antigen, a spike protein domain 1 of SARS-CoV-2 Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 Functionalized TiO 2 nanotube-based electrochemical biosensor for rapid detection of SARS-CoV-2 GenMark Receives FDA Emergency Use Authorization for its ePlex® SARS-CoV-2 Test, Inc, 2020 eSensor Technology ePlex®SARS-CoV-2 Test Assay Manual Inflammasomes: current understanding and open questions Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis Sputum cytology of patients with severe acute respiratory syndrome (SARS) Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis A structural analysis of M protein in coronavirus assembly and morphology Prospects of nanomaterials-enabled biosensors for COVID-19 detection Biosensors: frontiers in rapid detection of COVID-19 Rapid, ultrasensitive, and quantitative detection of SARS-CoV-2 using antisense oligonucleotides directed electrochemical biosensor chip Paper-based electrochemical biosensor for diagnosing COVID-19: Detection of SARS-CoV-2 antibodies and antigen Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation COVID-19 vaccines: modes of immune activation and future challenges Massively multiplexed nucleic acid detection with Cas13 iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2 CRISPR-Cas12-based detection of SARS-CoV-2 19 IgM/IgG rapid test COVID-19 IgM/IgG System COVID-19 Antigen Rapid Test Device Wantai SARS-CoV-2 Ag Rapid Test Kit BD Veritor™ System for Rapid Detection of SARS-CoV-2 COVID-19 Ag Rapid Test Device Xpert®Xpress SARS-CoV-2 Has Received FDA Emergency Use Authorization SARS-CoV-2 Detection VereCoV™ OneMix Detection Kit for VerePLEX™ Biosystem Clinical performance of the Luminex NxTAG CoV extended panel for SARS-CoV-2 detection in nasopharyngeal specimens from COVID-19 patients in Hong Kong ID NOW™ COVID-19 Molecular Cue COVID-19 Test In vitro diagnostics for COVID-19: State-of-the-art, future directions and role in pandemic response Clinical features of patients infected with 2019 novel coronavirus in